Tenax Therapeutics, Inc. – NASDAQ:TENX
Tenax Therapeutics stock price today
$6.09
-0.20
-3.33%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Tenax Therapeutics stock price monthly change
+88.62%
month
Tenax Therapeutics stock price quarterly change
+88.62%
quarter
Tenax Therapeutics stock price yearly change
+2050.17%
year
Tenax Therapeutics key metrics
Market Cap | 18.98M |
Enterprise value | N/A |
P/E | -0.05 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.37 |
PEG ratio | N/A |
EPS | -18.3 |
Revenue | N/A |
EBITDA | -2.59M |
Income | -2.50M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTenax Therapeutics stock price history
Tenax Therapeutics stock forecast
Tenax Therapeutics financial statements
| Jun 2023 | 0 | -1.10M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.97M | |
| Dec 2023 | 5.79K | -3.22M | -55709.83% |
| Mar 2024 | 0 | 3.79M |
| 2025 | 2M | -18.80M | -940.15% |
|---|---|---|---|
| 2026 | 4.15M | -16.64M | -400.52% |
| 2027 | 140.37M | 3.73M | 2.66% |
| 2028 | 250.59M | 5.55M | 2.22% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 14045499 | 823.84K | 5.87% |
|---|---|---|---|
| Sep 2023 | 11888909 | 602.21K | 5.07% |
| Dec 2023 | 11684627 | 3.58M | 30.69% |
| Mar 2024 | 14460264 | 2.03M | 14.04% |
| Jun 2023 | -922.96K | 1.60K | -99.90K |
|---|---|---|---|
| Sep 2023 | -2.08M | 0 | -171.28K |
| Dec 2023 | -1.17M | -1.24K | -174.46K |
| Mar 2024 | -5.16M | 0 | 7.92M |
Tenax Therapeutics alternative data
| Aug 2023 | 7 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 5 |
| Jun 2024 | 5 |
| Jul 2024 | 5 |
Tenax Therapeutics other data
8.75%
-13.47%
of TENX is owned by hedge funds
123.04K
-189.35K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2024 | 124980 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PROEHL GERALD T director | Pre-Funded Warrant | 31,654 | $0.01 | $317 | ||
Purchase | PROEHL GERALD T director | Warrant | 16,660 | $4.5 | $74,970 | ||
Purchase | PROEHL GERALD T director | Common Stock | 1,666 | $3 | $4,998 | ||
Purchase | DAVIDSON MICHAEL H. director | Pre-Funded Warrant | 47,500 | $0.01 | $475 | ||
Purchase | DAVIDSON MICHAEL H. director | Warrant | 25,000 | $4.5 | $112,500 | ||
Purchase | DAVIDSON MICHAEL H. director | Common Stock | 2,500 | $3 | $7,500 | ||
Option | DOOGAN DECLAN | Common Stock | 3,070,000 | N/A | N/A | ||
Option | DOOGAN DECLAN | Series B Preferred Stock | 3,070 | N/A | N/A | ||
Option | DAVIDSON MICHAEL H. | Series B Preferred Stock | 512 | N/A | N/A | ||
Option | RICH STUART officer: Chief Medical Officer | Common Stock | 3,581,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 8 Dec 2021 Issue date: 31 Mar 2022 |
Application LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) Filling date: 24 Aug 2021 Issue date: 23 Dec 2021 |
Application LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) Filling date: 15 Dec 2020 Issue date: 17 Jun 2021 |
Application Filling date: 19 Aug 2019 Issue date: 22 Oct 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2016 21 Mar 2017 | Q4 2016 Earnings Call Transcript |
| Q3 2016 10 Nov 2016 | Q3 2016 Earnings Call Transcript |
| Q2 2016 11 Aug 2016 | Q2 2016 Earnings Call Transcript |
| Q1 2016 19 May 2016 | Q1 2016 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Michael B. Jebsen CPA (1971) Advisor | $525,830 |
-
What's the price of Tenax Therapeutics stock today?
One share of Tenax Therapeutics stock can currently be purchased for approximately $6.09.
-
When is Tenax Therapeutics's next earnings date?
Unfortunately, Tenax Therapeutics's (TENX) next earnings date is currently unknown.
-
Does Tenax Therapeutics pay dividends?
No, Tenax Therapeutics does not pay dividends.
-
How much money does Tenax Therapeutics make?
Tenax Therapeutics has a market capitalization of 18.98M.
-
What is Tenax Therapeutics's stock symbol?
Tenax Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TENX".
-
What is Tenax Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Tenax Therapeutics?
Shares of Tenax Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Tenax Therapeutics's key executives?
Tenax Therapeutics's management team includes the following people:
- Mr. Michael B. Jebsen CPA Advisor(age: 54, pay: $525,830)
-
How many employees does Tenax Therapeutics have?
As Jul 2024, Tenax Therapeutics employs 5 workers, which is 29% less then previous quarter.
-
When Tenax Therapeutics went public?
Tenax Therapeutics, Inc. is publicly traded company for more then 31 years since IPO on 4 Apr 1994.
-
What is Tenax Therapeutics's official website?
The official website for Tenax Therapeutics is tenaxthera.com.
-
Where are Tenax Therapeutics's headquarters?
Tenax Therapeutics is headquartered at ONE Copley Parkway, Morrisville, NC.
-
How can i contact Tenax Therapeutics?
Tenax Therapeutics's mailing address is ONE Copley Parkway, Morrisville, NC and company can be reached via phone at +91 98552100.
Tenax Therapeutics company profile:
Tenax Therapeutics, Inc.
tenaxthera.comExchange:
NASDAQ
Full time employees:
5
Industry:
Biotechnology
Sector:
Healthcare
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
ONE Copley Parkway
Morrisville, NC 27560
Morrisville, NC 27560
CIK: 0000034956
ISIN: US88032L6056
CUSIP: 88032L209
